These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 7846205)

  • 1. An open clinical and biochemical study of ritanserin in acute patients with schizophrenia.
    Wiesel FA; Nordström AL; Farde L; Eriksson B
    Psychopharmacology (Berl); 1994 Feb; 114(1):31-8. PubMed ID: 7846205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy.
    Kapur S; Zipursky R; Jones C; Shammi CS; Remington G; Seeman P
    Arch Gen Psychiatry; 2000 Jun; 57(6):553-9. PubMed ID: 10839333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma prolactin and central D2 receptor occupancy in antipsychotic drug-treated patients.
    Nordström AL; Farde L
    J Clin Psychopharmacol; 1998 Aug; 18(4):305-10. PubMed ID: 9690696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation.
    Kapur S; Zipursky RB; Remington G; Jones C; DaSilva J; Wilson AA; Houle S
    Am J Psychiatry; 1998 Jul; 155(7):921-8. PubMed ID: 9659858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Striatal vs extrastriatal dopamine D2 receptors in antipsychotic response--a double-blind PET study in schizophrenia.
    Agid O; Mamo D; Ginovart N; Vitcu I; Wilson AA; Zipursky RB; Kapur S
    Neuropsychopharmacology; 2007 Jun; 32(6):1209-15. PubMed ID: 17077809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Time course of central nervous dopamine-D2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel) in patients with schizophrenia.
    Gefvert O; Bergström M; Långström B; Lundberg T; Lindström L; Yates R
    Psychopharmacology (Berl); 1998 Jan; 135(2):119-26. PubMed ID: 9497016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An open label trial of raclopride in acute schizophrenia. Confirmation of D2-dopamine receptor occupancy by PET.
    Farde L; Wiesel FA; Jansson P; Uppfeldt G; Wahlen A; Sedvall G
    Psychopharmacology (Berl); 1988; 94(1):1-7. PubMed ID: 3126517
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quetiapine: an effective antipsychotic in first-episode schizophrenia despite only transiently high dopamine-2 receptor blockade.
    Tauscher-Wisniewski S; Kapur S; Tauscher J; Jones C; Daskalakis ZJ; Papatheodorou G; Epstein I; Christensen BK; Zipursky RB
    J Clin Psychiatry; 2002 Nov; 63(11):992-7. PubMed ID: 12444812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients.
    Nordström AL; Farde L; Wiesel FA; Forslund K; Pauli S; Halldin C; Uppfeldt G
    Biol Psychiatry; 1993 Feb; 33(4):227-35. PubMed ID: 8097114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients.
    Nyberg S; Eriksson B; Oxenstierna G; Halldin C; Farde L
    Am J Psychiatry; 1999 Jun; 156(6):869-75. PubMed ID: 10360125
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of Antipsychotic Dose Reduction in Late-Life Schizophrenia: A Prospective Dopamine D2/3 Receptor Occupancy Study.
    Graff-Guerrero A; Rajji TK; Mulsant BH; Nakajima S; Caravaggio F; Suzuki T; Uchida H; Gerretsen P; Mar W; Pollock BG; Mamo DC
    JAMA Psychiatry; 2015 Sep; 72(9):927-34. PubMed ID: 26131622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Delayed normalization of central D2 dopamine receptor availability after discontinuation of haloperidol decanoate. Preliminary findings.
    Nyberg S; Farde L; Halldin C
    Arch Gen Psychiatry; 1997 Oct; 54(10):953-8. PubMed ID: 9337776
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dopamine D
    Vanover KE; Davis RE; Zhou Y; Ye W; Brašić JR; Gapasin L; Saillard J; Weingart M; Litman RE; Mates S; Wong DF
    Neuropsychopharmacology; 2019 Feb; 44(3):598-605. PubMed ID: 30449883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia.
    Kapur S; Zipursky RB; Remington G
    Am J Psychiatry; 1999 Feb; 156(2):286-93. PubMed ID: 9989565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Striatal D2 dopamine receptor characteristics in neuroleptic-naive schizophrenic patients studied with positron emission tomography.
    Hietala J; Syvälahti E; Vuorio K; Någren K; Lehikoinen P; Ruotsalainen U; Räkköläinen V; Lehtinen V; Wegelius U
    Arch Gen Psychiatry; 1994 Feb; 51(2):116-23. PubMed ID: 7905257
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased dopamine d(2) receptor occupancy and elevated prolactin level associated with addition of haloperidol to clozapine.
    Kapur S; Roy P; Daskalakis J; Remington G; Zipursky R
    Am J Psychiatry; 2001 Feb; 158(2):311-4. PubMed ID: 11156818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High levels of dopamine D2 receptor occupancy with low-dose haloperidol treatment: a PET study.
    Kapur S; Remington G; Jones C; Wilson A; DaSilva J; Houle S; Zipursky R
    Am J Psychiatry; 1996 Jul; 153(7):948-50. PubMed ID: 8659621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ritanserin antagonism of m-chlorophenylpiperazine effects in neuroleptic-free schizophrenics patients: support for serotonin-2 receptor modulation of schizophrenia symptoms.
    Abi-Saab W; Seibyl JP; D'Souza DC; Karper LP; Gueorgueva R; Abi-Dargham A; Wong ML; Rajhans S; Erdos JP; Heninger GR; Charney DS; Krystal JH
    Psychopharmacology (Berl); 2002 Jun; 162(1):55-62. PubMed ID: 12107618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ritanserin, a selective 5-HT2/1C antagonist, and negative symptoms in schizophrenia. A placebo-controlled double-blind trial.
    Duinkerke SJ; Botter PA; Jansen AA; van Dongen PA; van Haaften AJ; Boom AJ; van Laarhoven JH; Busard HL
    Br J Psychiatry; 1993 Oct; 163():451-5. PubMed ID: 7902766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical melperone treatment blocks D2-dopamine receptors in the human brain as determined by PET.
    Wiesel FA; Farde L; Halldin C
    Acta Psychiatr Scand Suppl; 1989; 352():30-4. PubMed ID: 2573239
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.